Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 8, 2026Clinical & Translational OncologyOpen Access

Challenges in the measurement and valuation of oncological treatments in Spain: recommendations and call to action

View Full Paper
Ask AI
Bookmark
Share

Authors

MGMaria Rosario García-CampeloJCJ. CorralFMFernando Moreno

Discussion

Loading...

Member takes

Overview

Expert panel analyzes challenges and provides recommendations for oncology treatment evaluation in Spain, indicating vital areas for improvement.

Key Points

  • This study aims to identify challenges in measuring the value of oncology treatments in Spain and offers recommendations for improvement.
  • A multidisciplinary expert panel of twelve professionals was convened to discuss value assessment challenges.
  • Panel participated in three structured sessions to identify key uncertainty sources and develop consensus statements.
  • External experts provided complementary input in tumor-specific characteristics and statistical methods.
  • The panel issued twelve recommendations, including tailored clinical endpoints and complementing overall survival with quality-of-life measures.
  • Proposed a national portfolio of endpoints and advocated for standardizing real-world evidence collection.
  • Recommendations included using advanced analytics like AI, flexible reimbursement models, and promoting stakeholder training.

Cite This Study

García-Campelo et al. (2026) studied this question.

synapsesocial.com/papers/69fd7f86bfa21ec5bbf0805bhttps://doi.org/10.1007/s12094-026-04323-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Significance of emerging clinical oncology endpoints in support of overall survival2022 · 10 citations
  2. 2Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries2024 · 26,093 citations
  3. 3Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer2018 · 64 citations
  4. 4Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology2017 · 82 citations
  5. 5Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non–Small Cell Lung Cancer Trials2017 · 106 citations